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ABSTRACT
Objective: To determine whether the obesity paradox exists in patients who undergo carotid
artery stenting (CAS) or carotid endarterectomy (CEA) for symptomatic carotid artery stenosis.
Methods: We combined individual patient data from 2 randomized trials (Endarterectomy vs
Angioplasty in Patients with Symptomatic Severe Carotid Stenosis and Stent-Protected Angio-
plasty vs Carotid Endarterectomy) and 3 centers in a third trial (International Carotid Stenting
Study). Baseline body mass index (BMI) was available for 1,969 patients and classified into 4
groups: ,20, 20–,25, 25–,30, and $30 kg/m2. Primary outcome was stroke or death, inves-
tigated separately for the periprocedural and postprocedural period (#120 days/.120 days
after randomization). This outcome was compared between different BMI strata in CAS and CEA
patients separately, and in the total group. We performed intention-to-treat multivariable Cox
regression analyses.
Results:Median follow-up was 2.0 years. Stroke or death occurred in 159 patients in the peripro-
cedural (cumulative risk 8.1%) and in 270 patients in the postprocedural period (rate 4.8/100
person-years). BMI did not affect periprocedural risk of stroke or death for patients assigned to
CAS (ptrend 5 0.39) or CEA (ptrend 5 0.77) or for the total group (ptrend 5 0.48). Within the total
group, patients with BMI 25–,30 had lower postprocedural risk of stroke or death than patients
with BMI 20–,25 (BMI 25–,30 vs BMI 20–,25; hazard ratio 0.72; 95% confidence interval
0.55–0.94).
Conclusions: BMI is not associated with periprocedural risk of stroke or death; however, BMI
25–,30 is associated with lower postprocedural risk than BMI 20–,25. These observations
were similar for CAS and CEA. Neurology® 2017;88:1–9
GLOSSARY
BMI 5 body mass index; CAS 5 carotid artery stenting; CEA 5 carotid endarterectomy; CI 5 confidence interval; CREST 5
Carotid Revascularization Endarterectomy vs Stenting Trial; EVA-3S 5 Endarterectomy vs Angioplasty in Patients with
Symptomatic Severe Carotid Stenosis; HR 5 hazard ratio; ICA 5 internal carotid artery; ICSS 5 International Carotid
Stenting Study; SPACE 5 Stent-Protected Angioplasty vs Carotid Endarterectomy.
In 2014, 39% of the worldwide population 18 years or older were overweight and 13% were
obese according to the WHO.1 Being overweight or obese is a major risk factor for several
vascular diseases and reduces median survival by 2–4 years in adults with body mass index (BMI)
30–35 kg/m2.2
Surprisingly, patients with BMI 30–35 kg/m2 had a better 30-day survival than patients with
lower BMI in a study on morbidity and mortality after various vascular interventions.3 This
*These authors contributed equally to this work.
From the Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (E.J.V., A.A., L.J.K.), Julius Center for Health Sciences and
Primary Care (E.J.V., J.P.G., A.A.), and Department of Radiology (J.H.), University Medical Center Utrecht, the Netherlands; IVPE (J.-P.B.),
Hopital Privé Paul D’Egine Champigny, France; Department of Neurology and Stroke Center (L.H.B.), University Hospital Basel, Switzerland;
Department of Brain Repair and Rehabilitation (L.H.B., M.M.B.), UCL Institute of Neurology, University College London, UK; Department of
Neurology (T.G.B.), Mayo Clinic, Jacksonville, FL; Clinical Trial Service Unit and Epidemiological Studies Unit (R.B.), Oxford University, UK;
Department of Neurology (D.C., J.-L.M.), Hôpital Sainte-Anne, Université Paris-Descartes, DHU Neurovasc Sorbonne Paris Cité, INSERM
U894, Paris, France; Department of Vascular and Endovascular Surgery/Vascular Center (H.-H.E.), Klinikum rechts der Isar, Technical University
Munich, Germany; Department of Vascular Surgery (G.F.), Medical University of Innsbruck, Austria; London School for Hygiene and Tropical
Medicine (J.G.); Nuffield Department of Surgical Sciences (A.H.), John Radcliffe Hospital, Oxford, UK; Department of Biostatistics (G.H.), UAB
School of Public Health, Birmingham, AL; Clinic for Radiology and Neuroradiology (O.J.), UKSH Campus Kiel, Germany; Cardiovascular
Associates of the Southeast (G.S.R.), Birmingham, AL; and Department of Neurology (P.A.R.), University of Heidelberg Medical School, Germany.
Coinvestigators are listed at Neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
© 2017 American Academy of Neurology 1
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
obesity paradox was also observed in patients
with manifest vascular diseases.4,5 In patients
undergoing carotid artery stenting (CAS),
a higher BMI was associated with lower mor-
tality after a mean follow-up of 2.4 years.6
Moreover, obese carotid endarterectomy
(CEA) patients with BMI 30–35 had a lower
30-day stroke risk than patients with BMI
18.5–25 kg/m2.7 In contrast, another study
has reported a higher 30-day mortality and
cardiac complication rate in obese CEA pa-
tients (BMI $30 kg/m2) compared with nor-
mal weight patients.8
To our knowledge, the association between
BMI and short- and long-term clinical out-
come following CAS and CEA among patients
with symptomatic internal carotid artery
(ICA) stenosis has not been examined together
in one analysis. Therefore, we studied the asso-
ciation between BMI and periprocedural and
postprocedural risk of stroke or death to inves-
tigate whether the obesity paradox exists in pa-
tients who undergo CAS or CEA for
symptomatic ICA stenosis.
METHODS Trials. The Carotid Stenosis Trialists’ Collabora-
tion pooled data from randomized controlled studies that ran-
domly assigned patients to undergo either CAS or CEA for
symptomatic carotid artery stenosis at the individual patient level:
the Endarterectomy vs Angioplasty in Patients with Symptomatic
Severe Carotid Stenosis (EVA-3S) trial (NCT 00190398),9 the
Stent-Protected Angioplasty vs Carotid Endarterectomy (SPACE)
trial (ISRCTN 57874028),10 the International Carotid Stenting
Study (ICSS) (ISRCTN 25337470),11 and the Carotid Revas-
cularization Endarterectomy vs Stenting Trial (CREST)
(NCT00004732).12 All patients had to have symptomatic mod-
erate to severe carotid artery stenosis caused by atherosclerosis,
which was defined as a lumen narrowing on imaging of $50%
according to North American Symptomatic Carotid Endarter-
ectomy Trial criteria.13 Patients were excluded if they had
recurrent stenosis after previous treatment of the ipsilateral ICA.
Detailed methods were described previously.14
Data collection. Baseline data on the following patient charac-
teristics were used for the current analysis: age, sex, history of
hypertension, hyperlipidemia, diabetes, coronary heart disease
(composite of myocardial infarction, angina, and prior coronary
surgery), peripheral artery disease, TIA or stroke, past or current
smoking, type of most recent event before randomization (retinal
ischemia or amaurosis fugax, TIA, or hemispheric stroke), and
modified Rankin Scale score.15,16 In addition, degree of ipsilateral
stenosis and presence of contralateral severe stenosis or occlusion
was recorded.
Baseline BMI was available for 1,969 patients included in
EVA-3S, SPACE, and ICSS. Height was not recorded in CREST,
and as such BMI was unavailable. For ICSS, we retrospectively
collected BMI in 264 out of 371 patients (71%) who were ran-
domized in 3 Dutch centers. BMI was missing in 18 EVA-3S
patients. Patients were classified into 4 groups according to their
BMI: ,20, 20–,25, 25–,30, and $30 kg/m2. Median dura-
tion of follow-up in patients with BMI data available was 7 years
in EVA-3S, 2 years in SPACE, and 4 years in ICSS.
Outcome events. Primary outcome event was the combination
of any stroke or death and was analyzed separately for the peripro-
cedural (#120 days after randomization) and postprocedural
period (.120 days after randomization) on an intention-to-
treat basis. The secondary outcome was ipsilateral stroke during
the procedural (#30 days after procedure) and postprocedural
period (.30 days after procedure). The analysis of the secondary
outcome was performed on a per-protocol basis and included
only those patients in whom the randomly assigned procedure
was initiated. All 3 trials uniformly defined stroke as the occur-
rence of acute symptoms of focal neurologic deficit that lasted for
more than 24 hours and were caused by intracranial vascular
disturbance, either ischemic or hemorrhagic.
Statistical analysis. Cumulative risks are provided for the
occurrence of primary and secondary outcome events in the peri-
procedural and procedural period; risk rates are provided for the
postprocedural period. We used Cox regression analyses to eval-
uate the association between BMI and the occurrence of primary
and secondary outcome events for each treatment group (CAS or
CEA) and for all patients combined. The results are presented as
hazard ratios (HRs) with corresponding 95% confidence intervals
(CIs). Normal BMI (20–,25 kg/m2) was used as reference cat-
egory. In addition, we calculated CAS-to-CEAHRs and tested for
the interaction between treatment and BMI in each BMI group.
Patients were excluded from the analysis of the postprocedur-
al period (.120 days after randomization or .30 days after
procedure) if they had a stroke, died, or withdrew from the study
during the periprocedural (#120 days after randomization for the
intention-to-treat analysis) or procedural (#30 days after proce-
dure for the per-protocol analysis) period. All Cox regression
analyses were adjusted for source trial and for factors that were
considered to be potential confounders of the association between
BMI and outcome (i.e., age, sex, and smoking [past or current]).
Cox regression analysis of postprocedural ipsilateral stroke risk
was adjusted only for source trial, since few events occurred dur-
ing this period. We additionally adjusted for presence of other
vascular risk factors at baseline and type of most recent event
before randomization. These factors were considered intermedi-
ates by which BMI affects vascular disease risk, as in previous
general population studies.2,17
The proportional hazards assumption was assessed visually
with log minus log survival plots. With linear test for trend anal-
ysis, we assessed the overall pattern of stroke or death and ipsilat-
eral stroke risk with increasing BMI. To achieve this, BMI group
was added as a continuous variable to the Cox regression models.
We performed a post hoc sensitivity analysis with all-cause
mortality as outcome. Furthermore, we combined patients in
the 2 highest BMI groups and examined postprocedural stroke
or death risk across 3 BMI groups: ,20, 20–,25, and $25
kg/m2. Also, we classified BMI into 6 groups and analyzed stroke
or death risk during the periprocedural and postprocedural
period. Finally, we compared baseline characteristics in ICSS
patients with and without BMI data available and performed
a sensitivity analysis of only the patients who were included in
EVA-3S and SPACE.
RESULTS Out of the 1,969 patients with BMI data
available, 963 patients underwent CAS and 1,006
underwent CEA (figure 1). Mean BMI was 26.7
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(64.1) kg/m2 in the total group. Within the group
with BMI ,20, 21 patients (34%) had BMI ,18.5
kg/m2. Within the group with BMI $30, 286 pa-
tients (81%) had BMI 30–,35 and 68 patients had
BMI $35 kg/m2. BMI was similarly distributed
across the 3 trials (figure e-1 at Neurology.org).
Table 1 provides the baseline characteristics of
each BMI group. Mean age was 68.9 (69.1) years
in the total group. The proportion of men was higher
in the groups with BMI $20 than in the group with
BMI ,20 kg/m2. The proportion of patients with a
history of hypertension or diabetes increased with
BMI. Patients with BMI 25–,30 were more likely
to have had a preceding TIA but less likely to have
had hemispheric stroke than patients with BMI ,25
kg/m2. Median duration of follow-up was 2.0 years
(interquartile range 2.0–5.0).
In the intention-to-treat analysis, stroke or death
occurred in 159 patients (cumulative risk 8.1%)
during the periprocedural period (#120 days after
randomization). BMI did not affect periprocedural
risk of stroke or death for patients assigned to either
CAS (ptrend 5 0.39) or CEA (ptrend 5 0.77) or for
the total group (ptrend 5 0.48) (table 2, figure 2A).
In the postprocedural period (.120 days after ran-
domization), 270 out of 1,751 patients had a stroke
or died (rate 4.8/100 person-years). In the total
group of patients, postprocedural stroke or death
risk was significantly lower for patients with BMI
25–,30 than for patients with BMI 20–,25 kg/
m2 (BMI 25–,30 vs BMI 20–,25; HR 0.72; 95%
CI 0.55–0.94; table 2, figure 2B). The periproce-
dural and postprocedural CAS-to-CEA HRs for
stroke or death risk did not differ across the BMI
groups (table e-1). When we classified BMI into 6
groups, periprocedural and postprocedural stroke or
death risk was comparable with BMI classified into 4
groups (table e-2).
Figure 1 Flow chart of patients included in the meta-analysis
BMI 5 body mass index; ITT 5 intention-to-treat; PP 5 per-protocol.
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Post hoc sensitivity analyses revealed that the
lower postprocedural stroke or death risk was mainly
due to a lower all-cause mortality risk in patients with
BMI 25–,30 compared to patients with BMI 20–,
25 kg/m2 (BMI 25–,30 vs BMI 20–,25; rate 3.0/
100 person-years vs 5.1/100 person-years; HR 0.64;
95% CI 0.47–0.86; table e-3). When we combined
patients in the 2 highest BMI groups, postprocedural
stroke or death risk remained significantly lower for
patients with BMI $25 kg/m2 (BMI $25 vs BMI
20–,25; HR 0.76; 95% CI 0.59–0.98).
Following per-protocol analysis, 119 out of 1,910
patients had an ipsilateral stroke (cumulative risk
6.2%) during the procedural period (#30 days after
procedure). Procedural ipsilateral stroke risk did not
differ across the BMI groups (table 3). In the post-
procedural period (.30 days after procedure), 35 out
of 1,755 patients had an ipsilateral stroke (rate 0.6/
100 person-years). Within the CEA group, patients
with BMI 25–,30 had a lower postprocedural ipsi-
lateral stroke risk than did patients with BMI 20–,
25 kg/m2 (table 3). Within the group with BMI
25–,30, patients treated with CAS had a higher
postprocedural ipsilateral stroke risk than did patients
treated with CEA (CAS-to-CEA HR 4.02; 95% CI
1.12–14.47; table e-1), with evidence for an inter-
action between treatment and BMI 25–,30 kg/m2
(interaction p 5 0.008).
Table 1 Baseline characteristics in each body mass index (BMI) group
BMI, kg/m2
<20 (n 5 62) 20–<25 (n 5 625) 25–<30 (n 5 928) ‡30 (n 5 354)
Age at randomization, y, mean (SD) 68.8 (610.1) 69.7 (69.7) 69.1 (68.7) 66.8 (68.6)
Male sex, n (%) 27 (44) 454 (73) 697 (75) 242 (68)
History, n (%)
Hypertension 32 (52) 409 (66) 711 (77) 295 (84)
Hyperlipidemiaa 27 (44) 325 (52) 502 (54) 207 (59)
Diabetes 8 (13) 138 (22) 230 (25) 134 (38)
Smoking (past or current) 40 (65) 358 (57) 555 (60) 215 (61)
Stroke or TIA >180 days before randomizationb 9 (26) 111 (41) 150 (43) 42 (35)
Coronary heart disease 7 (11) 134 (22) 221 (24) 84 (24)
Peripheral artery diseaseb 6 (17) 43 (16) 50 (14) 17 (14)
mRS score at baseline, n (%)
0 24 (39) 319 (51) 511 (55) 168 (48)
1 20 (32) 156 (25) 241 (26) 104 (29)
2 11 (18) 100 (16) 131 (14) 64 (18)
3 7 (11) 47 (8) 42 (5) 17 (5)
4 0 1 (,1) 2 (,1) 0
Blood pressure at baseline, mm Hg, mean (SD)
Systolic 140.0 (625.6) 143.9 (620.0) 144.9 (620.7) 145.0 (620.3)
Diastolicc 75.7 (614.7) 79.1 (611.2) 80.2 (611.0) 81.1 (610.7)
Degree of ipsilateral stenosis, n (%)
Moderate (50%–69%) 10 (16) 154 (25) 251 (27) 95 (27)
Severe (‡70%) 52 (84) 471 (75) 677 (73) 259 (73)
Contralateral severe stenosis (‡70%) or occlusion, n (%)d 10 (18) 81 (15) 103 (13) 31 (10)
Type of most recent event before randomization, n (%)
Retinal ischemia or amaurosis fugax 9 (15) 104 (17) 153 (16) 63 (18)
TIA 15 (24) 207 (33) 367 (40) 126 (36)
Hemispheric stroke 38 (61) 312 (50) 408 (44) 164 (46)
Abbreviations: BMI 5 body mass index; mRS 5 modified Rankin Scale; SPACE 5 Stent-Protected Angioplasty vs Carotid Endarterectomy.
aDefined as hyperlipidemia or taking lipid-lowering medication at randomization.
bData not collected in SPACE trial.
c Data not collected in carotid artery stenting patients.
dData missing in 269 SPACE patients.
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Cox regression analyses additionally adjusted for
presence of vascular risk factors and type of most
recent event yielded the same results as shown in
tables 2 and 3 (data not shown). Baseline character-
istics did not differ in ICSS patients with and without
BMI data available (table e-4). After exclusion of
ICSS patients for the sensitivity analysis of EVA-3S
and SPACE patients, stroke or death and ipsilateral
stroke risk was essentially the same as in all patients
with BMI data available (data not shown).
DISCUSSION In our study, BMI was not associated
with a higher periprocedural or postprocedural stroke
or death risk. Moreover, BMI 25–,30 kg/m2 was
associated with a lower postprocedural stroke or death
risk after CAS or CEA. This association persisted when
Table 2 Stroke or death risk in the periprocedural and postprocedural period
BMI, kg/m2a
Test for trend
p value<20 20–<25 25–<30 ‡30
Periprocedural period
CAS
No. 31 293 442 197
Events (cumulative risk), n (%) 2 (7) 25 (9) 43 (10) 16 (8)
BMI HRb 0.76 ref 1.19 1.22 0.39
95% CI 0.18–3.24 0.72–1.95 0.64–2.31
CEA
No. 31 332 486 157
Events (cumulative risk), n (%) 1 (3) 23 (7) 39 (8) 10 (6)
BMI HRb 0.43 ref 1.14 0.89 0.77
95% CI 0.06–3.20 0.68–1.91 0.42–1.87
Total group
No. 62 625 928 354
Events (cumulative risk), n (%) 3 (5) 48 (8) 82 (9) 26 (7)
BMI HRb 0.62 ref 1.19 1.03 0.48
95% CI 0.19–2.02 0.83–1.70 0.63–1.66
Postprocedural period
CAS
No. 29 261 382 173
Events (rate/100 person-years) 7 (6.6) 49 (5.5) 48 (4.1) 19 (3.8)
BMI HRb 1.48 ref 0.76 1.07 0.39
95% CI 0.66–3.30 0.51–1.13 0.62–1.84
CEA
No. 28 300 436 142
Events (rate/100 person-years) 8 (7.9) 62 (6.2) 56 (4.0) 21 (4.6)
BMI HRb 1.52 ref 0.68 0.81 0.05
95% CI 0.72–3.23 0.47–0.98 0.49–1.33
Total group
No. 57 561 818 315
Events (rate/100 person-years) 15 (7.2) 111 (5.9) 104 (4.0) 40 (4.2)
BMI HRb 1.52 ref 0.72 0.90 0.04
95% CI 0.88–2.63 0.55–0.94 0.62–1.29
Abbreviations: BMI 5 body mass index; CAS 5 carotid artery stenting; CEA 5 carotid endarterectomy; CI 5 confidence
interval; HR 5 hazard ratio; ref 5 reference category.
Risk of primary outcome (stroke or death) in periprocedural (#120 days after randomization) and postprocedural (.120
days after randomization) period in intention-to-treat analysis.
aNormal BMI (20–,25 kg/m2) is used as reference category.
bAdjusted for source trial, age, sex, smoking (past or current).
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patients with BMI 25–,30 and $30 kg/m2 were
combined. In a post hoc analysis, the lower post-
procedural stroke or death risk in patients with BMI
25–,30 seemed to be due to a significantly lower all-
cause mortality risk compared with patients whose
BMI was 20–,25 kg/m2. These observations were
similar for CAS and CEA and suggest the existence of
an obesity paradox for long-term outcome in over-
weight and obese patients who undergo CAS or CEA.
Being overweight or obese is an established risk
factor for primary stroke18 and mortality.2 In a large
meta-analysis, risk of first-ever ischemic stroke after 4
years of follow-up was higher in participants with
BMI $25 than in those with BMI ,25 kg/m2.18
In contrast, a higher BMI seems to protect from
future (vascular) events in patients who already had
a stroke; several studies have demonstrated a lower
risk of recurrent stroke,19 all-cause death,20,21 and vas-
cular death22 in overweight or obese patients ($25
kg/m2) compared with normal weight patients.
Previous research has found conflicting results on
how BMI affects stroke or death risk in patients who
underwent CAS or CEA. Two studies reported lower
all-cause mortality in CAS patients with higher BMI
after a follow-up of 2–4 years,6,23 but all-cause mor-
tality was only significantly lower for overweight
female and not for male CAS patients in one study.23
Incidence of death, stroke, or myocardial infarction
within 30 days after CAS did not vary among BMI
groups.6 For CEA patients, obesity (BMI 30–35) was
associated with a 50% reduction in 30-day stroke risk
compared to normal weight (BMI 18.5–25 kg/m2) in
one study,7 whereas 2 other studies found no associ-
ation between BMI and 30-day stroke risk.8,24 More-
over, a BMI of $35 was associated with higher
mortality and cardiac complication risk compared to
normal BMI (18.5–25 kg/m2) in one of the latter
studies.8 To our knowledge, there is no study that
investigated long-term effect of BMI on stroke or
death risk in CEA patients.
All but one of the aforementioned studies
included patients with both symptomatic and asymp-
tomatic ICA stenosis, which might explain the differ-
ences with our study findings.6–8,23 Patients with
asymptomatic ICA stenosis generally have a lower
stroke or death risk after carotid revascularization
than patients with symptomatic ICA stenosis.25
Therefore, associations between BMI and stroke or
death risk might also be different. In addition, the
prevalence of baseline characteristics and vascular risk
factors in our study population differs from previous
CAS or CEA studies. One of the previous CEA stud-
ies included patients who were registered in the Vet-
erans Affairs Surgical Quality Improvement Program
database, 98.6% of whom were male,8 while in our
study 72.1% of the patients were male.
Several hypotheses have been proposed to explain
the obesity paradox in patients with vascular disease
or after surgery. One explanation is that BMI does
not accurately account for the location of body fat tis-
sue. The amount of abdominal adipose tissue might
be higher in patients with normal weight (BMI 20–
25) compared to patients with BMI $25 kg/m2,
which is related to a higher risk of death.26 In addi-
tion, our study population consisted of elderly pa-
tients. Ideal BMI may be higher in these patients,
since low BMI is associated with higher mortality
through lower muscle mass, poor nutritional status,
and underlying chronic diseases. Furthermore, some
studies have suggested that paradoxes found in recur-
rent risk research, such as the obesity paradox, may be
caused by index event bias.27–29 Index event bias can
occur when patients are selected based on the occur-
rence of an earlier episode of the disease, in our case
stroke. Conditioning on this episode may induce an
inverse association between the risk factors for the
disease, even when these risk factors are not associated
with each other in the general population.29 Conse-
quently, the association between the risk factor of
Figure 2 Stroke or death risk in the periprocedural and postprocedural period
Hazard ratios of primary outcome (stroke or death) in each body mass index (BMI) group for
the total group of patients in the (A) periprocedural (#120 days after randomization) and (B)
postprocedural (.120 days after randomization) period. Normal BMI (20–,25 kg/m2) is used
as reference category.
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interest and recurrence of the event becomes under-
estimated or reversed.
Our results are in conflict with results from several
recent large-scale general population studies that
restricted their analysis to never-smokers or omitted
events during the first years of follow-up to limit
reverse causality.2,17,30 One of these studies combined
individual patient data from 239 prospective studies
and found lowest all-cause mortality at BMI 20–25
kg/m2, with a significant increase above and below
this range.30 Similarly, mortality by stroke increased
by around 40% for each 5 kg/m2 higher BMI above
25 kg/m2. However, smokers and people with preex-
isting cardiovascular disease, cancer, or respiratory
Table 3 Ipsilateral stroke risk in the procedural and postprocedural period
BMI, kg/m2a
Test for trend
p value<20 20–<25 25–<30 ‡30
Procedural period
CAS
No. 31 290 427 192
Events (cumulative risk), n (%) 2 (7) 19 (7) 35 (8) 12 (6)
BMI HRb 0.96 ref 1.28 1.21 0.49
95% CI 0.22–4.18 0.73–2.24 0.58–2.51
CEA
No. 31 314 475 150
Events (cumulative risk), n (%) 1 (3) 15 (5) 30 (6) 5 (3)
BMI HRb 0.63 ref 1.28 0.66 0.90
95% CI 0.08–4.86 0.69–2.38 0.24–1.82
Total group
No. 62 604 902 342
Events (cumulative risk), % 3 (5) 34 (6) 65 (7) 17 (5)
BMI HRb 0.84 ref 1.30 0.93 0.75
95% CI 0.26–2.75 0.86–1.98 0.52–1.67
Postprocedural period
CAS
No. 29 263 384 175
Events (rate/100 person-years) 0 (0) 2 (0.2) 11 (0.9) 4 (0.7)
BMI HRc NA ref 3.67 2.88 0.16
95% CI 0.81–16.58 0.53–15.79
CEA
No. 29 295 439 141
Events (rate/100 person-years) 2 (1.8) 8 (0.8) 3 (0.2) 5 (1.0)
BMI HRc 2.63 ref 0.25 1.27 0.37
95% CI 0.56–12.45 0.07–0.96 0.42–3.90
Total group
No. 58 558 823 316
Events (rate/100 person-years) 2 (0.9) 10 (0.5) 14 (0.5) 9 (0.9)
BMI HRc 2.01 ref 0.94 1.57 0.67
95% CI 0.44–9.20 0.42–2.12 0.64–3.88
Abbreviations: BMI 5 body mass index; CAS 5 carotid artery stenting; CEA 5 carotid endarterectomy; CI 5 confidence
interval; HR 5 hazard ratio; NA 5 not applicable; ref 5 reference category.
Risk of secondary outcome (ipsilateral stroke) in procedural (#30 days after procedure) and postprocedural (.30 days
after procedure) period in per-protocol analysis.
aNormal BMI (20–,25 kg/m2) is used as reference category.
bAdjusted for source trial, age, sex, smoking (past or current).
c Adjusted for source trial.
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disease were excluded from this study, which limits
comparability with our study population. We cannot
rule out the risk of bias due to reverse causality in our
study; we could not adjust for several potential con-
founders that are associated both with BMI and mor-
tality, such as history of cancer, renal dysfunction,
and chronic obstructive pulmonary disease, because
these data were not collected in the original trials. Yet
the risk of bias due to reverse causality may be limited
since patients with a life expectancy of ,2 years were
excluded from EVA-3S, SPACE, and ICSS. More-
over, Cox regression analysis yielded essentially the
same results when we excluded patients who died in
the first year after randomization and when we
restricted the analysis to mortality due to vascular
causes (data not shown).
One of the strengths of our study is the use of indi-
vidual patient data from 3 randomized controlled tri-
als. In addition, long-term follow-up data on the
occurrence of outcome events were available from
each trial. Finally, to our knowledge, this study is
the first to examine the association between BMI
and both short- and long-term outcome in CAS
and CEA patients with symptomatic ICA stenosis.
Our study has some limitations. First, BMI was
only available in a part of the ICSS patients who were
randomized in 3 Dutch centers. BMI might have
been measured more frequently in heavier patients
and therefore might not be missing randomly in ICSS
patients without BMI data. However, we obtained
comparable results when we performed a sensitivity
analysis of only EVA-3S and SPACE patients. Sec-
ond, the number of outcome events was low in the
group with BMI ,20 kg/m2 and in the analysis of
postprocedural ipsilateral stroke risk. Consequently,
HR estimates were imprecise. Third, the number of
patients with severe (BMI 35–,40) and very severe
(BMI$40) obesity within the group with BMI$30
kg/m2 was small and therefore not analyzed sepa-
rately, while more severe obesity could be a risk factor
after CAS or CEA. Fourth, measures of adiposity
other than BMI, such as waist circumference26 or
waist-to-height ratio,31 were more strongly associated
with risk of stroke or death in previous general pop-
ulation studies. In EVA-3S, SPACE, and ICSS, data
on waist circumference or waist-to-height ratio were
not collected. However, BMI is frequently used as
a measure of adiposity. Hence, our results can more
easily be compared with results from previous studies.
Fifth, data on lifestyle behavior such as diet, physical
activity, and use of medication at baseline (e.g., anti-
platelets, antihypertensives) were not available in our
study. Although these factors could confound the
association between BMI and clinical outcome after
CAS and CEA, we could not adjust for them in our
analysis. Finally, risk of other adverse outcomes such
as wound infections or cardiac complications was
higher in obese patients who underwent CEA com-
pared to normal weight patients in a previous study.7
Risk of these outcomes was not examined in the cur-
rent study but should be kept in mind when deciding
on what treatment to offer to individual patients.
We found no evidence for a higher stroke or death
risk in overweight or obese patients undergoing CAS
or CEA for symptomatic ICA stenosis. Our results
suggest the existence of an obesity paradox for long-
term stroke or death risk in overweight or obese
CAS or CEA patients. Thus, with regards to short-
and long-term stroke or death risk, we found no rea-
son to withhold revascularization for symptomatic
ICA stenosis from overweight or obese patients.
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